AVXL
Anavex Life Sciences Corp.
Price Chart
Latest Quote
$2.67
+0.15 (+5.75%)
Current Price
| Previous Close | $2.52 |
| Open | $2.60 |
| Day High | $2.77 |
| Day Low | $2.56 |
| Volume | 937,388 |
Stock Information
| Shares Outstanding | 92.67M |
| Cash Equivalents | $131.75M |
| Net Income | $-39.95M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $246.97M |
| EPS (TTM) | $-0.46 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $101.78M |
| Income | $-39.95M |
| Book/sh | $1.37 |
| Cash/sh | $1.42 |
| Employees | 34 |
Financial Ratios
| Quick Ratio | 20.81 |
| Current Ratio | 20.87 |
Returns & Margins
| ROA | -21.56% |
| ROE | -33.63% |
Ownership
| Insider Ownership | 3.12% |
| Institutional Ownership | 43.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.85 |
| P/B | 1.95 |
Analyst Data
| Recommendation | none |
| Target Price | $20.00 |
Technical Indicators
| SMA20 | $2.68 |
| SMA50 | $3.01 |
| SMA200 | $5.04 |
| RSI | 39.54 |
| ATR | 0.1850 |
| Shares Float | 89.78M |
| Short Float | 21.15% |
| Short Ratio | 18.49 |
| Volatility | 1.12 |
| Rel Volume | 0.84 |
Performance History
| Week | +8.33% |
| Month | -7.47% |
| Quarter | -37.44% |
| 6 Months | -35.63% |
| YTD | -27.58% |
| Year | -69.05% |
| 3 Years | -69.21% |
| 5 Years | -82.71% |
| 10 Years | -33.71% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.66 | 937,388 |
| 2026-06-16 | $2.52 | 951,000 |
| 2026-06-15 | $2.50 | 934,200 |
| 2026-06-12 | $2.50 | 1,222,100 |
| 2026-06-11 | $2.50 | 974,800 |
| 2026-06-10 | $2.46 | 921,700 |
| 2026-06-09 | $2.54 | 869,000 |
| 2026-06-08 | $2.62 | 895,000 |
| 2026-06-05 | $2.57 | 942,400 |
| 2026-06-04 | $2.82 | 937,700 |
| 2026-06-03 | $2.64 | 1,054,000 |
| 2026-06-02 | $2.79 | 2,421,400 |
| 2026-06-01 | $2.98 | 1,593,000 |
| 2026-05-29 | $3.03 | 1,314,100 |
| 2026-05-28 | $2.94 | 1,419,200 |
| 2026-05-27 | $2.76 | 1,157,300 |
| 2026-05-26 | $2.71 | 924,400 |
| 2026-05-22 | $2.69 | 1,119,000 |
| 2026-05-21 | $2.71 | 954,700 |
| 2026-05-20 | $2.75 | 880,500 |
| 2026-05-19 | $2.67 | 1,563,200 |
| 2026-05-18 | $2.88 | 937,100 |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
đ° Latest News
Penny Stocks To Watch In May 2026
Simply Wall St. âĸ 2026-05-29T12:05:45Z
Exploring High Growth Tech Stocks In The US Market May 2026
Simply Wall St. âĸ 2026-05-28T11:38:13Z
CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus
InvestorsHub âĸ 2026-05-06T14:52:36Z
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-04T13:43:08Z
Exploring Three High Growth Tech Stocks In The US Market
Simply Wall St. âĸ 2026-04-29T11:38:25Z
What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks
Insider Monkey âĸ 2026-04-26T15:13:13Z
Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference
MarketBeat âĸ 2026-04-15T04:05:34Z
3 Promising Penny Stocks With At Least $200M Market Cap
Simply Wall St. âĸ 2026-04-02T18:05:05Z
High Growth Tech Stocks in US for March 2026
Simply Wall St. âĸ 2026-03-31T17:38:47Z
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?
Barchart âĸ 2026-03-26T14:10:58Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $0 | $964,000 | $0 |
| Total Expenses | $51,371,000 | $52,802,000 | $55,738,000 | $50,986,000 |
| Other Income Expense | $316,000 | $2,480,000 | $2,678,000 | $2,419,000 |
| Other Non Operating Income Expenses | $648,000 | $2,291,000 | $2,718,000 | $3,323,000 |
| Net Non Operating Interest Income Expense | $4,678,000 | $7,320,000 | $5,555,000 | $947,000 |
| Interest Expense Non Operating | $0 | $0 | $964,000 | $0 |
| Operating Expense | $51,371,000 | $52,802,000 | $55,738,000 | $50,986,000 |
| Other Operating Expenses | $-37,000 | $-75,000 | $-25,000 | - |
| General And Administrative Expense | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Interest Income | $4,678,000 | $7,320,000 | $5,555,000 | $947,000 |
| Interest Income | $4,678,000 | $7,320,000 | $6,519,000 | $947,000 |
| Normalized Income | $-46,045,000 | $-43,191,000 | $-47,465,000 | $-47,263,840 |
| Net Income From Continuing And Discontinued Operation | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Total Operating Income As Reported | $-51,408,000 | $-52,877,000 | $-55,763,000 | $-50,986,000 |
| Net Income Common Stockholders | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income Including Noncontrolling Interests | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Net Income Continuous Operations | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Pretax Income | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,620,000 |
| Interest Income Non Operating | $4,678,000 | $7,320,000 | $6,519,000 | $947,000 |
| Operating Income | $-51,371,000 | $-52,802,000 | $-55,738,000 | $-50,986,000 |
| Per Share | ||||
| Diluted EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 |
| Basic EPS | $-0.54 | $-0.52 | $-0.60 | $-0.62 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-189,840 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,045,000 | $-43,191,000 | $-46,501,000 | $-46,716,000 |
| Total Unusual Items | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| Total Unusual Items Excluding Goodwill | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| EBITDA (Bullshit earnings) | $-46,377,000 | $-43,002,000 | $-46,541,000 | $-47,620,000 |
| EBIT | $-46,377,000 | $-43,002,000 | $-46,541,000 | $-47,620,000 |
| Diluted Average Shares | $85,289,447 | $83,468,049 | $79,787,596 | $76,909,993 |
| Basic Average Shares | $85,289,447 | $83,468,049 | $79,787,596 | $76,909,993 |
| Diluted NI Availto Com Stockholders | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Gain On Sale Of Security | $-332,000 | $189,000 | $-40,000 | $-904,000 |
| Research And Development | $37,592,000 | $41,838,000 | $43,717,000 | $37,916,000 |
| Selling General And Administration | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Other Gand A | $13,816,000 | $11,039,000 | $12,046,000 | $13,070,000 |
| Tax Provision | - | $0 | $7,000 | $358,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Assets | $103,815,000 | $135,567,000 | $154,386,000 | $152,705,000 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $103,815,000 | $135,567,000 | $154,386,000 | $152,705,000 |
| Other Current Assets | $429,000 | $931,000 | $653,000 | $354,000 |
| Receivables | $809,000 | $2,449,000 | $2,709,000 | $3,193,000 |
| Taxes Receivable | $809,000 | $2,449,000 | $2,709,000 | $3,193,000 |
| Cash Cash Equivalents And Short Term Investments | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Cash And Cash Equivalents | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Prepaid Assets | - | - | - | $354,162 |
| Current Deferred Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,946,000 | $15,304,000 | $12,534,000 | $10,214,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $8,946,000 | $15,304,000 | $12,534,000 | $10,214,000 |
| Current Deferred Liabilities | $805,000 | $842,000 | $917,000 | $444,000 |
| Payables And Accrued Expenses | $6,579,000 | $12,935,000 | $10,257,000 | $8,472,000 |
| Payables | $4,249,000 | $9,627,000 | $4,322,000 | $3,825,000 |
| Accounts Payable | $4,249,000 | $9,627,000 | $4,322,000 | $3,825,000 |
| Equity | ||||
| Common Stock Equity | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Equity Gross Minority Interest | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Stockholders Equity | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Retained Earnings | $-382,448,000 | $-336,071,000 | $-293,069,000 | $-245,564,000 |
| Other | ||||
| Ordinary Shares Number | $86,668,521 | $84,795,517 | $82,066,511 | $77,942,815 |
| Share Issued | $86,668,521 | $84,795,517 | $82,066,511 | $77,942,815 |
| Tangible Book Value | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Invested Capital | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Working Capital | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Total Capitalization | $94,869,000 | $120,263,000 | $141,852,000 | $142,491,000 |
| Additional Paid In Capital | $477,230,000 | $456,249,000 | $434,839,000 | $387,977,000 |
| Capital Stock | $87,000 | $85,000 | $82,000 | $78,000 |
| Common Stock | $87,000 | $85,000 | $82,000 | $78,000 |
| Current Deferred Revenue | $805,000 | $842,000 | $917,000 | $444,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,562,000 | $1,527,000 | $1,360,000 | $1,298,000 |
| Current Accrued Expenses | $2,330,000 | $3,308,000 | $5,935,000 | $4,647,000 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Cash Flow From Continuing Operating Activities | $-39,044,000 | $-30,812,000 | $-27,785,000 | $-24,238,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Financing Cash Flow | $9,434,000 | $11,975,000 | $29,651,000 | $21,288,000 |
| Cash Flow From Continuing Financing Activities | $9,434,000 | $11,975,000 | $29,651,000 | $21,288,000 |
| Net Common Stock Issuance | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Common Stock Issuance | $9,198,000 | $11,284,000 | $27,875,000 | $20,985,000 |
| Net Other Financing Charges | - | - | - | $-707,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $125,000 | $300,000 | $136,000 | $327,000 |
| End Cash Position | $102,577,000 | $132,187,000 | $151,024,000 | $149,158,000 |
| Beginning Cash Position | $132,187,000 | $151,024,000 | $149,158,000 | $152,108,000 |
| Changes In Cash | $-29,610,000 | $-18,837,000 | $1,866,000 | $-2,950,000 |
| Proceeds From Stock Option Exercised | $2,943,000 | $691,000 | $1,776,000 | $1,010,000 |
| Change In Working Capital | $-4,216,000 | $2,752,000 | $2,505,000 | $5,361,000 |
| Change In Other Working Capital | $-37,000 | $-75,000 | $473,000 | - |
| Change In Payables And Accrued Expense | $-6,321,000 | $2,845,000 | $1,847,000 | $-584,000 |
| Change In Accrued Expense | $-943,000 | $-2,460,000 | $1,350,000 | $330,000 |
| Change In Payable | $-5,378,000 | $5,305,000 | $497,000 | $-914,000 |
| Change In Account Payable | $-5,378,000 | $5,305,000 | $497,000 | $-914,000 |
| Change In Prepaid Assets | $502,000 | $-278,000 | $-299,000 | $1,000 |
| Change In Receivables | $1,640,000 | $260,000 | $484,000 | $5,944,000 |
| Stock Based Compensation | $11,549,000 | $9,438,000 | $16,370,000 | $18,379,000 |
| Net Income From Continuing Operations | $-46,377,000 | $-43,002,000 | $-47,505,000 | $-47,978,000 |
| Other Non Cash Items | - | - | $845,000 | - |
Fetched: 2026-06-17